- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2022-2030
When disposable medical devices first became popular, the biopharmaceutical business produced single-use films using "off-the-shelf" components sourced from other sectors, like the food industry.
Manufacturers have learned through a variety of experiences and studies on the safety of medical grade materials over the years that it was not a good idea to utilise materials that weren't particularly created and intended for use with medications.
The industry is currently concentrating on creating single-use films that are suitable and better suited to fulfil the rigorous standards of the biomanufacturing industry.
When a single polymer is unable to satisfy every need of a certain application, coextrusion is the answer. This method enables the right placement of materials with various qualities while maintaining each distinct substance as independent layers.
The Global biopharma film market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2022 to 2030.
Two new ready-to-use film coating products, INSTACOAT QD and INSTACOAT T2F, have been introduced by Ideal Cures, an Indian company with its headquarters in Mumbai, India.
INSTACOAT QD, a quick-disintegrating film coating product, is revolutionary for pharmaceutical applications because it offers quick film disintegration within 3â30 seconds.
Talc and TiO2 are not present in Ideal Cures' outstanding ready-to-use coating product, INSTACOAT T2F. This product was created in response to the numerous assumptions, queries, and worries over the potential carcinogenicity of talc and titanium dioxide.
As a result, their usage is discouraged in the US and Europe.
Ideal Cures' mission is to offer the greatest industry solutions by consistently creating fresh, cutting-edge products. As part of their commitment to help the pharmaceutical sector with its demand for better drug delivery systems and regulatory compliances with these two products, they intended to achieve yet another milestone.
In order to develop a pristine, worry-free material that is compatible with bioprocessing materials, Cytiva and SEE agreed to form a strategic cooperation. The main objective was to create a high-quality film that was created and produced especially for bioprocessing using the extensive product portfolio and industry knowledge of Cytiva as well as the material experience and polymer expertise of SEE.
The partnership between Cytiva and SEE was meant to address the challenges with the current film structures in the current biopharma market as the impact of extractables and leachables (E&L) on product stability became more visible in relation to single-use technology (SUT).
Galena Biopharma, a commercial partner of MonoSol Rx, has introduced Zuplenz (ondansetron) oral soluble film in the United States. MonoSol Rx is a specialty pharmaceutical company that uses its PharmFilm drug delivery technology to develop treatments that improve patient outcomes and address unmet needs.
The creator of PharmFilm, Monosol Rx, is the industry pioneer in the creation of oral soluble films for pharmaceuticals. PharmFilm permits the oral dissolution of a film to administer pharmacological drugs.
With Sealed Air Corporation, a major producer of primary films for pharmaceutical solutions, GE Healthcare's Life Sciences division has decided to advance a long-term partnership.
A new film developed by the two companies can be used in a variety of GE's single-use product applications. Through this agreement, single-use providers will be able to meet market needs for increased performance, supply chain control, and material/supplier transparency by delivering the next generation of purposely designed and manufactured films for bioprocessing applications.
| Sl no | Topic |
| 1 | Market Segmentation |
| 2 | Scope of the report |
| 3 | Abbreviations |
| 4 | Research Methodology |
| 5 | Executive Summary |
| 6 | Introduction |
| 7 | Insights from Industry stakeholders |
| 8 | Cost breakdown of Product by sub-components and average profit margin |
| 9 | Disruptive innovation in the Industry |
| 10 | Technology trends in the Industry |
| 11 | Consumer trends in the industry |
| 12 | Recent Production Milestones |
| 13 | Component Manufacturing in US, EU and China |
| 14 | COVID-19 impact on overall market |
| 15 | COVID-19 impact on Production of components |
| 16 | COVID-19 impact on Point of sale |
| 17 | Market Segmentation, Dynamics and Forecast by Geography, 2022-2030 |
| 18 | Market Segmentation, Dynamics and Forecast by Product Type, 2022-2030 |
| 19 | Market Segmentation, Dynamics and Forecast by Application, 2022-2030 |
| 20 | Market Segmentation, Dynamics and Forecast by End use, 2022-2030 |
| 21 | Product installation rate by OEM, 2022 |
| 22 | Incline/Decline in Average B-2-B selling price in past 5 years |
| 23 | Competition from substitute products |
| 24 | Gross margin and average profitability of suppliers |
| 25 | New product development in past 12 months |
| 26 | M&A in past 12 months |
| 27 | Growth strategy of leading players |
| 28 | Market share of vendors, 2022 |
| 29 | Company Profiles |
| 30 | Unmet needs and opportunity for new suppliers |
| 31 | Conclusion |
| 32 | Appendix |
© 2017-2025 Mobility Foresights Pvt Ltd. All rights reserved.